|Treatment of bleeding peptic ulcers : A meta-analysis of 21 randomized controlled trials evaluating proton pump inhibitors for bleeding ulcers (with or without endoscopic therapy) found a significant and consistent reduction in the risk of rebleeding. In contrast, studies on H2 antagonists have generally produced disappointing results. A meta-analysis concluded that there was a possible minor benefit with intravenous H2 antagonists in bleeding gastric ulcers but no benefit with duodenal ulcers. The relative efficacy of the proton pump inhibitors may be due to their superior ability to maintain a gastric pH at a level above 6.0, and thus protect an ulcer clot from fibrinolysis.|
| Mechanism of action:
Cimetidine competitively inhibits the action of histamine at the histamine H2-receptors of the parietal cells and thus is a histamine H2-receptor antagonist.
Cimetidine is not an anticholinergic agent. Studies have shown that cimetidine inhibits both daytime and nocturnal basal gastric acid secretion. Cimetidine also inhibits gastric acid secretion stimulated by food, histamine, pentagastrin, caffeine and insulin.
Active ulcer: Oral: 800 mg orally at bedtime or 300mg orally four times daily or 400 mg orally twice daily. IM/IV: 300mg every 6 hours or 37.5 mg/hr continuous infusion.
Active bleed: 37.5 mg/hr continuous IV (maximum 2400mg/day).
Gastric hypersecretory conditions: 300 to 600mg every 6 hours.
Renal Dosing: >40 ml/min: no change || 20-40 ml/min: give usual dose q8h or give 75% of usual dose. || 0-20 ml/min: Usual dose q12h or give 50% of usual dose.
| Dosing- Adults:
Treatment of active ulcer: 300 mg at bedtime or 150 mg twice daily
Maintenance of healed ulcer: 150 mg/day at bedtime
Gastric ulcer: 150 mg twice daily or 300 mg at bedtime
GERD: 150 mg twice daily
Meal-induced heartburn, acid indigestion, and sour stomach: 75 mg tablet [OTC] twice daily, 30 to 60 minutes prior to consuming food or beverages
Helicobacter pylori eradication (unlabeled use): 150 mg twice daily; requires combination therapy
Dosing adjustment in renal impairment:
| Dosing- Adults:
Duodenal ulcer: Oral: Treatment: 150 mg twice daily, or 300 mg once daily after the evening meal or at bedtime; maintenance: 150 mg once daily at bedtime
Helicobacter pylori eradication: 150 mg twice daily; requires combination therapy
Pathological hypersecretory conditions:
I.V.: Continuous infusion for Zollinger-Ellison: 1 mg/kg/hour; measure gastric acid output at 4 hours, if >10 mEq or if patient is symptomatic, increase dose in increments of 0.5 mg/kg/hour; doses of up to 2.5 mg/kg/hour have been used
Gastric ulcer, benign: Oral: 150 mg twice daily; maintenance: 150 mg once daily at bedtime
Erosive esophagitis: Oral: Treatment: 150 mg 4 times/day; maintenance: 150 mg twice daily
Prevention of heartburn: Oral: Zantac® 75 [OTC]: 75 mg 30-60 minutes before eating food or drinking beverages which cause heartburn; maximum: 150 mg in 24 hours; do not use for more than 14 days
Patients not able to take oral medication:
Elderly: Ulcer healing rates and incidence of adverse effects are similar in the elderly, when compared to younger patients; dosing adjustments not necessary based on age alone
Dosing adjustment in renal impairment: Adults: Clcr<50 mL/minute:
Hemodialysis: Adjust dosing schedule so that dose coincides with the end of hemodialysis
IVP: Ranitidine (usually 50 mg) should be diluted to a total of 20 mL with NS or D5W and administered over at least 5 minutes.
Continuous I.V. infusion: Administer at 6.25 mg/hour and titrate dosage based on gastric pH by continuous infusion over 24 hours
National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.
The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user’s use of or reliance upon this material.PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. Read the disclaimer